Navigation Links
Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors

TORONTO, Jan. 28 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that Dr. Michael Gresser has joined its Board of Directors as an independent director. Trillium Chairman Dr. Michael Moore commented: "It is a great pleasure to welcome such an experienced biotech executive as Dr. Gresser to the Board. His widely acclaimed contribution to drug discovery and development in the immune-inflammatory field will greatly benefit Trillium."

Trillium's overall strategy is to build and solidify its reputation as a premier immunology company, by creating a broad and innovative pipeline of proprietary biologic product opportunities. The company has already captured long-term value and de-risked some of its projects through a series of partnerships with multinational companies. Trillium also has a demonstrated ability to identify and access promising early-stage technologies, and is on track to announce the in-licensing of additional projects in the near future, strengthening its existing immunology franchise.

"We are building a leading company in the immunology space. With his years of drug development experience, Dr. Gresser is an ideal director to assist in achieving Trillium's goals", added Dr. Michael Cross, a member of Trillium's Board of Directors and Partner, GrowthWorks Capital. "In building Trillium, our focus is on delivering outstanding science and creating strong alliances with world-class partners. Dr. Gresser's substantial background and success in these areas will be of great value as we move forward."

About Dr. Michael Gresser:

Dr. Gresser received his PhD in Biochemistry in 1976 and after postdoctoral studies at the Molecular Biology Institute at UCLA he joined the Department of Chemistry at Simon Fraser University in Burnaby, British Columbia. In 1988 Dr. Gresser Joined the Merck Frosst Center for Therapeutic Research in Kirkland, Quebec as Director of Biochemistry. Over the next twelve years he progressed to Executive Director of Biochemistry and Molecular Biology and his team worked on a variety of small molecule drug discovery programs, resulting in the introduction of numerous molecules into clinical trials. Two of these molecules, Singulair and Vioxx, became products. In 2000 Dr. Gresser joined Amgen Inc. in Thousand Oaks, California, as Vice President, Research Inflammation, where he remained until April, 2006. His team at Amgen worked on many molecular targets, introducing numerous small molecules, human antibodies, and other proteins into development. Currently Dr. Gresser serves as CSO of Oxford BioTherapeutics, and is also Visiting Scholar at the Molecular Biology Institute at UCLA.

About Trillium:

Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, TTI-1612, is a recombinant growth factor that is being developed for the treatment of interstitial cystitis (IC) and the prevention of necrotizing enterocolitis (NEC). Trillium has broad portfolio preclinical immunology programs, including two that target the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. In addition, the company has an FcRIIa-specific humanized monoclonal antibody in development for treatment of immune complex-mediated inflammatory diseases.

Trillium has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies. The Company is supported by three premier venture capital investors: Vengrowth Private Equity Partners, Growthworks Capital and BDC Capital.

SOURCE Trillium Therapeutics Inc.

SOURCE Trillium Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Trillium and Biogen Idec enter into global license agreement
2. Trillium Strengthens its Board of Directors
3. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
4. Biodefense Industry Response to New WMD Report Card
5. New Industry Research Identifies "Operational Gap" in Clinical Trial Portfolio Management
6. A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs
7. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
8. Ethanol Blend Reduction in Brazil Makes Sense Provided 90-Day Deadline is Respected, Says Brazilian Sugarcane Industry Association
9. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
10. Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010
11. Goble & Associates Creative Work Awarded at Advertising Industry Competitions
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
Breaking Biology Technology:
(Date:10/27/2015)... Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ... so that they can be quantitatively analyzed with SMI,s ... Germany , October 28-29, 2015. SMI,s Automated Semantic ... eye tracking videos created with SMI,s Eye Tracking ...
(Date:10/26/2015)... Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern authentication ... , today announced the launch of its latest version ... unified platform enabling organizations to use standards-based authentication that ... Nok Nok S3 Authentication Suite is ideal for organizations ...
(Date:10/23/2015)... and GOLETA, California , October ... conference, BIOPAC and SensoMotoric Instruments (SMI) announce a mobile ... tracking data captured during interactive real-world tasks ... play integration of their established wearable solutions for eye ... synchronize gaze behavior captured with SMI Eye Tracking ...
Breaking Biology News(10 mins):